59PD - Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT] - Finn, R S; Kudo, M; Cheng, A-L (Ann Oncol, 2018)